Entrada Therapeutics reports Q2 2022 net loss of $23.2M; cash runway into 2H 2024

Entrada Therapeutics, Inc.

2022-Q2 EPS reported -$1.43

Cash, cash equivalents and marketable securities $244.3M as of June 30, 2022, sufficient into 2H 2024.
Net loss $23.2M vs $9.9M in Q2 2021; R&D $16.2M (up from $6.8M), G&A $7.3M (up from $3.1M).
On track to file IND for ENTR-601-44 (Duchenne) in Q4 2022; ENTR-701 named as first DM1 clinical candidate.
Appointed Karla MacDonald as Chief Corporate Affairs Officer.
Entered collaboration with Myotonic Dystrophy Clinical Research Network for natural history study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.